David Kelly has over 30 years of experience as a finance executive in the biopharmaceutical industry. From September 2014 to January 2020, Mr. Kelly held several roles with Horizon Therapeutics plc, a biopharmaceutical company listed on Nasdaq and headquartered in Dublin, Ireland, including as the Executive Vice President, Managing Director, Ireland, a Director of its Irish operating subsidiaries and Company Secretary. Prior to joining Horizon, Mr. Kelly served as Chief Financial Officer for Vidara Therapeutics, and was previously Chief Financial Officer of AGI Therapeutics. He also served as Senior Vice President of Warner Chilcott, a fully integrated specialty pharmaceutical company. While at Warner Chilcott, he led the company's successful IPO on Nasdaq. In addition, Mr. Kelly also held roles in Elan Corporation and KPMG. 

Mr. Kelly holds a Bachelor's degree in Economics from Trinity College, Dublin and is also a member of the Institute of Chartered Accountants in Ireland (ACA).

Ms. Hecht has over 25 years of experience as a corporate executive in the life science industry and currently serves as Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a speciality pharmaceutical company. From January 2019 to October 2021, Ms. Hecht served as senior vice president, general counsel and corporate secretary of Xeris Pharmaceuticals, Inc. Before Xeris, Ms. Hecht served as Managing Director and Chief Legal and Administrative Officer for Auven Therapeutics, a global biotechnology and pharmaceutical private equity firm. Ms. Hecht was previously a member of the Board of Directors of Neos Therapeutics (Nasdaq: NEOS) where she chaired the Nominating and Governance Committee and also served on the Board of Directors of Aytu BioScience Inc. (Nasdaq: AYTU) following its acquisition of Neos Therapeutics. Ms. Hecht is a graduate of Amherst College and Harvard Law School and started her career as an attorney specializing in intellectual property and corporate transactions at Willkie Farr & Gallagher (NY) and then Kirkland & Ellis (NY). She has established and led legal, compliance, licensing, human resources, and security departments at companies including Durata Therapeutics, Sun Products, MedPointe Inc. (formerly known as Carter-Wallace Inc.), Warner Chilcott PLC, ChiRex Ltd., and Alpharma Inc.

Joe Whalen has over 30 years of experience in the biopharmaceutical industry, leading and supporting transactions involving licensing, acquisitions, and strategic alliances. Mr. Whalen was among the first 20 employees when he joined Horizon Therapeutics plc in 2010 and led or supported many of Horizon’s acquisitions as Senior Vice President of Business Development & Alliances until October 2023.  From October 2023 to April 2024, he served as a senior vice president of Amgen Inc., following its acquisition of Horizon Therapeutics plc for $28.3 billion.  Prior to Horizon/ Amgen, Mr. Whalen held Business Development and Finance roles at Baxter Healthcare and Searle Pharmaceuticals. 

Currently Mr. Whalen is a principal at North Glen Advisors, a business consulting firm, and is also on the board of directors of the Colorectal Cancer Alliance serving as Treasurer.  Mr. Whalen was previously on the board of directors of iBIO, a life sciences industry association that represents life sciences employees at various organisations. 

Mr. Whalen earned an MBA from the University of Illinois and a Bachelor’s degree in Business from the University of Notre Dame.

Ms. Hecht has over 25 years of experience as a corporate executive in the life science industry and currently serves as Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a speciality pharmaceutical company. From January 2019 to October 2021, Ms. Hecht served as senior vice president, general counsel and corporate secretary of Xeris Pharmaceuticals, Inc. Before Xeris, Ms. Hecht served as Managing Director and Chief Legal and Administrative Officer for Auven Therapeutics, a global biotechnology and pharmaceutical private equity firm. Ms. Hecht was previously a member of the Board of Directors of Neos Therapeutics (Nasdaq: NEOS) where she chaired the Nominating and Governance Committee and also served on the Board of Directors of Aytu BioScience Inc. (Nasdaq: AYTU) following its acquisition of Neos Therapeutics. Ms. Hecht is a graduate of Amherst College and Harvard Law School and started her career as an attorney specializing in intellectual property and corporate transactions at Willkie Farr & Gallagher (NY) and then Kirkland & Ellis (NY). She has established and led legal, compliance, licensing, human resources, and security departments at companies including Durata Therapeutics, Sun Products, MedPointe Inc. (formerly known as Carter-Wallace Inc.), Warner Chilcott PLC, ChiRex Ltd., and Alpharma Inc.

David Kelly has over 30 years of experience as a finance executive in the biopharmaceutical industry. From September 2014 to January 2020, Mr. Kelly held several roles with Horizon Therapeutics plc, a biopharmaceutical company listed on Nasdaq and headquartered in Dublin, Ireland, including as the Executive Vice President, Managing Director, Ireland, a Director of its Irish operating subsidiaries and Company Secretary. Prior to joining Horizon, Mr. Kelly served as Chief Financial Officer for Vidara Therapeutics, and was previously Chief Financial Officer of AGI Therapeutics. He also served as Senior Vice President of Warner Chilcott, a fully integrated specialty pharmaceutical company. While at Warner Chilcott, he led the company's successful IPO on Nasdaq. In addition, Mr. Kelly also held roles in Elan Corporation and KPMG. 

Mr. Kelly holds a Bachelor's degree in Economics from Trinity College, Dublin and is also a member of the Institute of Chartered Accountants in Ireland (ACA).

Joe Whalen has over 30 years of experience in the biopharmaceutical industry, leading and supporting transactions involving licensing, acquisitions, and strategic alliances. Mr. Whalen was among the first 20 employees when he joined Horizon Therapeutics plc in 2010 and led or supported many of Horizon’s acquisitions as Senior Vice President of Business Development & Alliances until October 2023.  From October 2023 to April 2024, he served as a senior vice president of Amgen Inc., following its acquisition of Horizon Therapeutics plc for $28.3 billion.  Prior to Horizon/ Amgen, Mr. Whalen held Business Development and Finance roles at Baxter Healthcare and Searle Pharmaceuticals. 

Currently Mr. Whalen is a principal at North Glen Advisors, a business consulting firm, and is also on the board of directors of the Colorectal Cancer Alliance serving as Treasurer.  Mr. Whalen was previously on the board of directors of iBIO, a life sciences industry association that represents life sciences employees at various organisations. 

Mr. Whalen earned an MBA from the University of Illinois and a Bachelor’s degree in Business from the University of Notre Dame.

David Kelly has over 30 years of experience as a finance executive in the biopharmaceutical industry. From September 2014 to January 2020, Mr. Kelly held several roles with Horizon Therapeutics plc, a biopharmaceutical company listed on Nasdaq and headquartered in Dublin, Ireland, including as the Executive Vice President, Managing Director, Ireland, a Director of its Irish operating subsidiaries and Company Secretary. Prior to joining Horizon, Mr. Kelly served as Chief Financial Officer for Vidara Therapeutics, and was previously Chief Financial Officer of AGI Therapeutics. He also served as Senior Vice President of Warner Chilcott, a fully integrated specialty pharmaceutical company. While at Warner Chilcott, he led the company's successful IPO on Nasdaq. In addition, Mr. Kelly also held roles in Elan Corporation and KPMG. 

Mr. Kelly holds a Bachelor's degree in Economics from Trinity College, Dublin and is also a member of the Institute of Chartered Accountants in Ireland (ACA).

Ms. Hecht has over 25 years of experience as a corporate executive in the life science industry and currently serves as Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a speciality pharmaceutical company. From January 2019 to October 2021, Ms. Hecht served as senior vice president, general counsel and corporate secretary of Xeris Pharmaceuticals, Inc. Before Xeris, Ms. Hecht served as Managing Director and Chief Legal and Administrative Officer for Auven Therapeutics, a global biotechnology and pharmaceutical private equity firm. Ms. Hecht was previously a member of the Board of Directors of Neos Therapeutics (Nasdaq: NEOS) where she chaired the Nominating and Governance Committee and also served on the Board of Directors of Aytu BioScience Inc. (Nasdaq: AYTU) following its acquisition of Neos Therapeutics. Ms. Hecht is a graduate of Amherst College and Harvard Law School and started her career as an attorney specializing in intellectual property and corporate transactions at Willkie Farr & Gallagher (NY) and then Kirkland & Ellis (NY). She has established and led legal, compliance, licensing, human resources, and security departments at companies including Durata Therapeutics, Sun Products, MedPointe Inc. (formerly known as Carter-Wallace Inc.), Warner Chilcott PLC, ChiRex Ltd., and Alpharma Inc.